The size of the Haemostatic Agents Market in the Asia Pacific is forecasted to increase at a promising CAGR from 2022 to 2027.
Y-O-Y growth in the number of trauma and surgical cases in the APAC region and technology advances are some of the factors propelling the market forward. An increase in the number of surgical procedures is one of the key drivers of APAC's Haemostatic agents market growth. Surgical care is required to address a variety of health disorders, including cardiovascular illnesses, traumas, cancer, obstructed labor, birth abnormalities, and other conditions, as recognized by WHO and several other international organizations. In addition, Y-O-Y rise in the incidence of hemorrhage post-surgery and the growing emphasis on blood control are further estimated to accelerate the APAC region's market growth. Furthermore, technological advancements in surgical procedures, such as robot-assisted surgery and an aging population, are expected to drive the APAC hemostatic agents market.
The demand for hemostats has risen in tandem with the prevalence of chronic diseases, cesarean deliveries, fatal traumas, and significant organ procedures. These medications enable patients with hemostatic illnesses and nonanatomic and sensitive structures to avoid blood loss during surgical procedures. Its widespread use among healthcare professionals has contributed to its widespread adoption and helped to reduce treatment costs. Furthermore, due to technological advancements, notable manufacturers have produced absorbable adjunctive hemostats that assist experts in managing disruptive bleeding more effectively than in prior ways.
However, the APAC market for hemostatic agents is expected to be hampered by the high frequency of blood clotting disorders in countries such as China and India and a lack of information about hemostatic diagnostics in the Asia Pacific. Rural areas with high per capita income have increased their use of diagnostic and therapeutic agents, putting a strain on patient care. Certain government criteria and stringent norms have been implemented to strengthen the healthcare infrastructure.
This research report on the Asia Pacific haemostatic agents market has been segmented and sub-segmented into the following categories:
Regionally, Asia-Pacific is expected to grow rapidly in the coming years, as is evident from the high CAGR value for the region. In addition to having the highest growth rate, the region also has the third-highest market share. The region's rapid growth can be attributed to the developing stature of countries such as India and China.
The increased knowledge of the advantages of biosurgery over traditional surgical approaches is one of the primary reasons driving regional market expansion. In addition, a growing focus on healthcare technical developments for creating new and innovative goods and an increasing need for minimally invasive surgery are expected to boost the APAC market.
According to the Centers for Disease Control and Prevention, the prevalence rate of hemophilia, a bleeding disorder, is 1 in every 5000 male births. Due to the fact that this illness can only be treated by surgery, proper bleeding control equipment is essential.
KEY MARKET PLAYERS:
Companies dominating the Asia Pacific Haemostatic Agents Market profiled in this report are Ethicon, Pfizer, Baxter International, R. Bard, The Medicines Company, Anika Therapeutics, Advanced Medical Solutions, Integra LifeSciences, B Braun Melsungen, Gelita Medical, Equimedical, Vascular Solutions, Marine Polymer Technologies, and Z-Medica.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com